Heidelberg

The German Cancer Research Center (DKFZ) assumes a dual role within DKTK. It serves as the core center of the DKTK and hosts the central DKTK Coordination Office, which supports and connects cross-site structures and processes. In addition, together with the National Center for Tumor Diseases (NCT) Heidelberg, it forms the local DKTK Translation Center in Heidelberg. DKFZ, which is a member of the Helmholtz Association, Germany’s largest research organization, ranks among the leading cancer research centers worldwide. The NCT Heidelberg brings together patient-centered research and clinical care under one roof to rapidly translate new findings into clinical practice.

The DKTK Translation Center Heidelberg serves as a strategic anchor for national precision oncology by acting as the central bridge between fundamental cancer research at the DKFZ and its clinical application within university medical centers. In recent years, the DKTK has sharpened its focus, increasingly concentrating on preclinical translational and trial-enabling research. In close alignment with the investigator-initiated trial (IIT)-driven mission of the expanding NCT, a seamless translational continuum has emerged, encompassing both the transfer of insights from basic research into clinical application and the systematic feedback of clinical observations into research (reverse translation).

The scientific core of the Heidelberg Translation Center consists of four DKTK departments and one junior research group. Around 130 researchers contribute to the DKTK’s research projects, working groups, and platforms. Under the coordination of Heidelberg-based DKTK scientists, numerous collaborations have been initiated and successful translational research projects have been launched. Research activities at the DKTK Translational Center Heidelberg are structured into five focus areas: i) Data-driven molecular stratification integrates high-quality biomaterials from precision oncology programs with advanced multi-omics approaches, tumor microenvironment analyses, and drug sensitivity testing to identify prognostic markers, molecular signatures, and novel therapeutic targets. These activities are closely linked to ii) innovative therapies, which aim to translate molecular and immunological insights into new treatment approaches, and iii) reverse translation, which feeds clinical insights back into research. iv) Precision oncology diagnostics focuses on innovative molecular analytics and the early implementation of new technologies. v) The prevention focus aims to develop innovative precision strategies by leveraging molecular risk profiles and biomarker-based screening approaches to enable personalized and cost-effective cancer prevention.

At the Heidelberg site, numerous DKTK infrastructures and platforms are (co-)coordinated. As the core center, the DKTK drives the development of technological and scientific infrastructures as well as research platforms accessible to all partner sites, thereby strengthening the mission of translational cancer research. The central coordination of the DKTK School of Oncology is also based in Heidelberg and focuses on training researchers working in the field of translational research, including Medical Scientists, Clinician Scientists, and data scientists.